Chronic lithium treatment attenuates intracellular calcium mobilization.
D000328:Adult; D001402:B-Lymphocytes / Q000187:drug effects / Q000821:virology; D001714:Bipolar Disorder / Q000188:drug therapy; D002118:Calcium / Q000378:metabolism*; D016022:Case-Control Studies; D002452:Cell Count; D002460:Cell Line; D002472:Cell Transformation, Viral / Q000187:drug effects; D016009:Chi-Square Distribution; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D016257:Fura-2 / Q000378:metabolism; D004854:Herpesvirus 4, Human / Q000378:metabolism; D006706:Homeostasis / Q000187:drug effects*; D006801:Humans; D042541:Intracellular Space / Q000187:drug effects* / Q000378:metabolism; D008094:Lithium / Q000494:pharmacology* / Q000627:therapeutic use; D008246:Lysophospholipids / Q000494:pharmacology; D008297:Male; D015999:Multivariate Analysis; D019284:Thapsigargin / Q000494:pharmacology; D013997:Time Factors
D004791:Enzyme Inhibitors; D008246:Lysophospholipids; D019284:Thapsigargin; D008094:Lithium; C032881:lysophosphatidic acid; D002118:Calcium; D016257:Fura-2